The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers

Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer: Charting the Course: Treatment Approaches for dMMR Endometrial Cancer

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care

This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience.  The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for equitable and individualized care treatment plans that aim to improve patient outcomes.   Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment.  Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs.  The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints.  Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments.   All content will be aligned with current regulatory guidelines and appropriate for independent medical education (IME), with a clear distinction between on-label use and emerging data requiring further validation.

Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer First Installment

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

Beyond the Image: New Opportunities in Gynecologic Cancer Testing

Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. This 90-minute course explores the evolving role of ctDNA in identifying disease recurrence and assessing treatment response—potentially earlier than imaging or traditional biomarkers.   Participants will receive an in-depth overview of the biological basis of ctDNA detection, the current clinical evidence supporting its utility, and its integration into clinical workflows. Case-based discussions will illustrate real-world applications, showcasing how ctDNA can optimize decisions on surveillance and therapeutic strategy. The program will also critically assess limitations and challenges of ctDNA-based MRD testing, including issues with sensitivity, false positives, access, and cost.   In alignment with a fair and balanced approach, the course will also explore other MRD detection modalities such as radiologic imaging, CA-125, and histopathology, highlighting comparative strengths and contexts for use. The program engages clinicians to learn how to interpret ctDNA MRD data and apply it effectively within a multidisciplinary care framework.

The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers

This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning.   Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making.  This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear.   This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.